ClinicalTrials.gg
CompletedNCT01568749Updated Nov 24, 2014

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

A Phase 1 interventional study of Paracetamol and Paracetamol formulation 1 in Analgesia, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-24.

Sponsored by GlaxoSmithKline · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.

Enrollment
7th of 12
14 · median 15
Started
2008
the only one that year
Phase 1
3 of 28
none open now
Registered
4th of 28
by date

Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1, and was the 4th registered.

Ornithine Carbamoyltransferase Deficiency Disease

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Open to participants now

6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, or all of them as a file.
02

Study summary

A study investigating the pharmacokinetic profiles of four extended release paracetamol formulations

03

Conditions studied

  • Analgesia

Keywords

  • otc
  • Analgesia
  • Paracetamol
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Age:Aged 18 to 50 years inclusive.
  • (BMI):Body Mass Index must be in the range 19 - 28 kg/m2.
  • Compliance:Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • General Health:Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination.
  • :Females of who are, in the opinion of the investigator, practicing a reliable method of contraception.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy:Women who are pregnant or who have a positive serum pregnancy test.
  • Breast-feeding:Women who are breast-feeding.
  • Allergy/Intolerance:Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Clinical Study/Experimental Medication:a) Participation in another clinical study or receipt of an drug within 30 days of the screening visit. b) Previous participation in this study.
  • Substance abuse:Recent history (within the last 5 years) of alcohol or other substance abuse.
  • Personnel:An employee of the sponsor or the study site or members of their immediate family.
  • Disease: a) Current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure). b) Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures.
  • Vegetarians:Subjects who are vegetarian.
  • Hepatitis and Screening:Positive screening for Serum Surface Antigen, or Human Immunodeficiency Virus (HIV).
  • Medications:Current (within 14 days of screening) or regular use of any prescription, OTC, herbal medicine or drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing, (e.g. barbiturates, theophylline, cimetidine, or erythromycin).
  • Smoking:Non-smokers of less than 3 months or current use of nicotine-containing products.
  • Blood:Subject has donated or experienced significant blood loss within 56 days of Visit 2, donated plasma within 7 days of Visit 2, or has a value of = 12.0 g/dL.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
14 participants (actual)

Study arms

  • Active comparator
    Standard paracetamol

    Marketed formulation

    Drug: Paracetamol

  • Experimental
    Formulation 1

    Paracetamol formulation 1

    Drug: Paracetamol formulation 1

  • Experimental
    Formulation 2

    Paracetamol formulation 2

    Drug: Paracetamol Formulation 2

  • Experimental
    Formulation 3

    Paracetamol formulation 3

    Drug: Paracetamol formulation 3

  • Experimental
    Formulation 4

    Paracetamol formulation 4

    Drug: Paracetamol formulation 4

Interventions

  • Paracetamol

  • DrugParacetamol formulation 1

    Paracetamol

  • DrugParacetamol Formulation 2

    Paracetamol

  • DrugParacetamol formulation 3

    Paracetamol

  • DrugParacetamol formulation 4

    paracetamol

06

What researchers measure

Primary outcomes

  1. Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.

    Time frame: Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.

Secondary outcomes

  1. Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.

    Time frame: Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.

07

Study locations

1 site
  • MDS Pharma Services ARIZONA
    Phoenix, Arizona 85044, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Apr 2, 2012
Start
Dec 2008
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Nov 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01568749
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Dec 2008
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Nov 24, 2014

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion